Dapagliflozin approved in US for chronic kidney disease

Approval, following a priority review, was based on results from the DAPA-CKD trial where dapagliflozin reduced the risk of worsening renal function, onset of end stage kidney disease or risk of cardiovascular disease or renal death by 39% vs placebo in CKD stages 2-4.

Source:

PharmaTimes